AC Immune Says Antibody Responses Detected in Phase 1b/2 Trial of ACI-24 in Alzheimer's Disease

MT Newswires Live06-30

AC Immune (ACIU) said Tuesday that interim data from its phase 1b/2 trial of its immunotherapy candidate ACI-24 showed antibody responses at every dose level in patients with prodromal Alzheimer's disease.

The drug candidate was also found to be generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities-edema, according to the company.

The analysis covered 74 patients across three cohorts treated for 12 months with ACI-24, the company said.

AC Immune said it is now testing an enhanced version of the therapy using an additional adjuvant in a fourth group of patients.

Shares of AC Immune were down more than 11% in premarket activity Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647058559?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647058559","market":"hk","top_or_hot":-1,"title":"AC Immune Says Antibody Responses Detected in Phase 1b/2 Trial of ACI-24 in Alzheimer's Disease","media":"MT Newswires Live","content":"<html><body><p> AC Immune (ACIU) said Tuesday that interim data from its phase 1b/2 trial of its immunotherapy candidate ACI-24 showed antibody responses at every dose level in patients with prodromal Alzheimer's disease.</p><p>The drug candidate was also found to be generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities-edema, according to the company.</p><p>The analysis covered 74 patients across three cohorts treated for 12 months with ACI-24, the company said.</p><p>AC Immune said it is now testing an enhanced version of the therapy using an additional adjuvant in a fourth group of patients.</p><p>Shares of AC Immune were down more than 11% in premarket activity Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AC Immune Says Antibody Responses Detected in Phase 1b/2 Trial of ACI-24 in Alzheimer's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAC Immune Says Antibody Responses Detected in Phase 1b/2 Trial of ACI-24 in Alzheimer's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-30 21:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AC Immune (ACIU) said Tuesday that interim data from its phase 1b/2 trial of its immunotherapy candidate ACI-24 showed antibody responses at every dose level in patients with prodromal Alzheimer's disease.</p><p>The drug candidate was also found to be generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities-edema, according to the company.</p><p>The analysis covered 74 patients across three cohorts treated for 12 months with ACI-24, the company said.</p><p>AC Immune said it is now testing an enhanced version of the therapy using an additional adjuvant in a fourth group of patients.</p><p>Shares of AC Immune were down more than 11% in premarket activity Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4113","symbol_name":"食品零售","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2647058559","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647058559","pubTimestamp":1782825567,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AC Immune  said Tuesday that interim data from its phase 1b/2 trial of its immunotherapy candidate ACI-24 showed antibody responses at every dose level in patients with prodromal Alzheimer's disease.The drug candidate was also found to be generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities-edema, according to the company.The analysis covered 74 patients across three cohorts treated for 12 months with ACI-24, the company said.AC Immune said it is now testing an enhanced version of the therapy using an additional adjuvant in a fourth group of patients.Shares of AC Immune were down more than 11% in premarket activity Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4113":"食品零售","ACIU":"AC Immune SA","BK4139":"生物科技","ACI":"艾伯森"},"translate_title":"AC Immune表示在ACI-24治疗阿尔茨海默病的1b/2期试验中检测到抗体反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACIU":1,"ACI":1.5},"content_text":"AC Immune (ACIU) said Tuesday that interim data from its phase 1b/2 trial of its immunotherapy candidate ACI-24 showed antibody responses at every dose level in patients with prodromal Alzheimer's disease.The drug candidate was also found to be generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities-edema, according to the company.The analysis covered 74 patients across three cohorts treated for 12 months with ACI-24, the company said.AC Immune said it is now testing an enhanced version of the therapy using an additional adjuvant in a fourth group of patients.Shares of AC Immune were down more than 11% in premarket activity Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647058559","isCrawlerRequest":true}